Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy
- Design
- Randomized trial · 84 participants · Biomarker outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all participants had treated HIV with lipohypertrophy and BMI ≥ 25 kg/m² (median 32.9, described as obese), mean age 49; diabetes and active cardiovascular disease were excluded.
- Could weight loss explain it?
- PossiblyNo weight, HbA1c or visceral-fat change is reported for the 84 analysed participants and no mediation analysis was done; models adjust for baseline sex, BMI, hsCRP and sCD163, which addresses confounding, not mediation. The authors suggest visceral fat reduction may drive the clock effects.
- Study tier
- Study tier 3LOW: randomized and double-blind but small (84 with paired samples), single-centre, 32 weeks, post hoc and exploratory, with biomarker-only outcomes and p-values not adjusted across 17 clocks: a biomarker-only randomized comparison.
- Assessment
- Version 3 · Two independent AI reviews agreed · Nov 11, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This post hoc analysis of a randomized, double-blind trial measured blood DNA-methylation aging clocks in 84 adults with HIV and abdominal fat build-up (lipohypertrophy) who took weekly semaglutide or placebo for 32 weeks. Several clocks were associated with slower aging on semaglutide, for example PhenoAge by 4.9 years per year and DunedinPACE about 9% slower. Many other clocks, including most first-generation clocks and an intrinsic capacity clock, showed no significant difference. These are biomarkers, not health outcomes, and the analysis was exploratory and not planned in advance.
01Findings
What the study reported
- Drugs
- Semaglutide
- Comparator
- placebo (volume-matched saline injections)
- Dose
- 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, then 1.0 mg weekly through week 32
- Route
- subcutaneous
- Treatment duration
- 32 weeks
- Primary outcome
- annualized change in DNA-methylation epigenetic aging clocks from baseline to week 32 (post hoc; not prespecified in the parent trial)
- Effect
- Adjusted semaglutide vs placebo: PhenoAge -4.9 years/year (p = 0.004), PCGrimAge -3.1 (p = 0.007), GrimAge V2 -2.3 (p = 0.009), OMICmAge -2.2 (p = 0.009), RetroAge -2.2 (p = 0.030), DunedinPACE -0.09 units (9% slower, p = 0.01); not significant: DNAmFitAge (P = 0.323), AdaptAge, CausAge, DamAge, Horvath, Hannum, PCHorvath1, PCHorvath2 and the intrinsic capacity clock (P = 0.312)
- 95% confidence interval
- PhenoAge: 95% CI −8.16 to −1.63
- P value
- p = 0.004 (PhenoAge); p-values not adjusted for multiple comparisons
- Follow-up
- 32 weeks
- Adverse events
- not reported
- Limitations
- A post hoc, exploratory biomarker analysis of a single-centre trial with 84 participants and 32 weeks of follow-up, in an HIV-specific population, without correction for multiple comparisons; blood-based clocks are statistical predictors, not clinical outcomes.
Who was studied
- Mean age
- 49 ± 12 years
- Age min
- 18
- Sex distribution
- 42% women (35 of 84); men 67% of the semaglutide group vs 49% of placebo
- Bmi min
- 25
- Obesity status
- overweight or obesity required (BMI ≥ 25 kg/m²); median BMI 32.9
- Diabetes status
- excluded
- Cvd status
- excluded (active cardiovascular disease)
- Baseline condition
- HIV-associated lipohypertrophy (treated HIV on stable ART)
- Sample size
- 84
- Inclusion exclusion
- adults ≥18 with HIV-1 on stable ART, HIV-1 RNA < 400 copies/mL, BMI ≥ 25, lipohypertrophy by waist criteria; diabetes and active cardiovascular disease excluded
Study quality details
- Study design
- Randomized controlled trial
- Sample size
- 84
- Randomization
- yes
- Blinding
- double-blind
- Comparator
- placebo (volume-matched saline injections)
- Follow up duration
- 32 weeks
- Outcome type
- biomarker
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- 95% CIs reported; 84 participants; p-values not adjusted for multiple comparisons across 17 clocks; no sample-size calculation (post hoc)
- Risk of bias
- not assessed
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- National Institutes of Health (R01DK121619; PubMed grants: NIAID, NIDDK, NCATS); Clinical and Translational Science Collaborative of Northern Ohio; James B. Pendleton Charitable Trust; San Diego Center for AIDS Research
- Industry funded
- No
- Manufacturer
- not stated in source
- Sponsor role
- not reported
- Author conflicts
- One author consults for Merck, GlaxoSmithKline/ViiV and Gilead; one advises TruDiagnostic and two are TruDiagnostic employees; the other authors declare no competing interests.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- GLP-1 receptor agonists slow biological aging or extend healthspan in humans.Consistent, but doesn't test the claim
Post hoc analysis of a 32-week randomized trial in adults with HIV-associated lipohypertrophy (semaglutide n = 45; placebo n = 39): several epigenetic clocks ran slower with semaglutide (PhenoAge -4.9 years/year, p = 0.004; DunedinPACE 9% slower, p = 0.01) and others did not differ. Epigenetic aging was not pre-specified and no functional or healthspan outcome was measured.
04Source
The source, as retrieved
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). The parent trial's primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic aging was not pre-specified. To address this gap, we profiled peripheral-blood DNA methylation (DNAm) at baseline and week 32 to assess semaglutide versus placebo on first-, second-, and third-generation epigenetic aging measures. In adjusted analyses, semaglutide reduced epigenetic aging across multiple second- and third-generation clocks, including PhenoAge ( - 4.9 years/year, p = 0.004), PCGrimAge ( - 3.1, p = 0.007), GrimAge V2 ( - 2.3, p = 0.009), OMICmAge ( - 2.2, p = 0.009), RetroAge ( - 2.2, p = 0.030), and DunedinPACE ( - 0.09 units, 9% slower, p = 0.01). Systems-based clocks showed parallel reductions in inflammation, brain, and heart aging measures. The post hoc design, modest sample size, HIV-specific cohort, and 32-week follow-up limit generalizability. Prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Nov 11, 2026 | 42156721 first ingestion |